Log In Get Started
Press Releases April 30, 2026 04:00 PM

Brookfield Property Partners Declares Quarterly Dividends on Listed Preferred Units

Brookfield Property Partners Declares Quarterly Dividends on Preferred Units Payable June 2026

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
BPYPP

Brookfield Property Partners announces the declaration of quarterly distributions for its Nasdaq-listed preferred units BPYPP, BPYPO, BPYPN, and BPYPM for the quarter ending June 30, 2026. The dividends per unit range from $0.359375 to $0.40625 and will be paid to holders of record on June 1, 2026. Brookfield Property Partners is a leading global real estate company with a diverse portfolio including office, retail, multifamily, logistics, hospitality, and other real estate sectors.

Brookfield Property Partners Declares Quarterly Dividends on Listed Preferred Units
BPYPP
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Quarterly dividends declared on four classes of Nasdaq-listed preferred units (BPYPP, BPYPO, BPYPN, BPYPM).
  • Dividend amounts range from $0.359375 to $0.40625 per unit, payable on June 30, 2026, with record date June 1, 2026.
  • Brookfield Property Partners operates a diversified global real estate portfolio including office, retail, multifamily, and logistics sectors.

All dollar references are in U.S. dollars, unless noted otherwise. 

BROOKFIELD NEWS, April 30, 2026 (GLOBE NEWSWIRE) -- Brookfield Property Partners (“BPY” or the "Partnership") announced today that the Board of Directors has declared quarterly distributions on the Partnership’s Class A Nasdaq-listed BPYPP, BPYPO, BPYPN and BPYPM (TSX: BPYP.PR.A) preferred units of $0.40625 per unit, $0.3984375 per unit, $0.359375 per unit and $0.390625 per unit, respectively, payable on June 30, 2026, to holders of record at the close of business on June 1, 2026.

Brookfield Property Partners

Brookfield Property Partners is one of the world’s premier real estate companies. We own and operate iconic properties in the world’s major markets, and our global portfolio includes office, retail, multifamily, logistics, hospitality, single-family rentals, manufactured housing, student housing and self-storage.

Brookfield Property Partners is a subsidiary of Brookfield Corporation (NYSE: BN, TSX: BN). More information is available at www.brookfield.com.


Contact:                                                                                                                                                                                                                                                                                                                                                                     
Keren Dubon
Investor Relations
Tel.: (212) 618-3440
Email: Keren.Dubon@brookfield.com


Risks

  • Market risks impacting real estate valuation and income streams could affect future dividend payments.
  • Interest rate fluctuations may influence borrowing costs and real estate investment returns, impacting distributions.
  • Sector-specific performance risks in retail, office, or hospitality markets could materially affect Brookfield's portfolio income stability.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026